Since 2016, the number of venture capital deals and the total deal volume per year have significantly increased in the Diagnostics sector. In Europe, the deal volume doubled, while the number of deals rose by ~1.4 times. By comparison, the deal volume in the United States tripled while the number of deals remained relatively stable. Unsurprisingly, the 2020 deal volume in the U.S. significantly exceeds that in Europe, by 7.4 times to be precise.
Another interesting development is the nearly doubled deal volume in the U.S. between 2019 and 2020 while the number of deals only increased by 2 deals. This is mainly driven by larger deals closed in 2020, for example the EUR 227m Series B round of Thrive Earlier Detection or the EUR 155m Series C round of Genalyte.